BCDABullishRegulatory consultation completion for marketing applicationnews
Medium materiality6/10
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
Nov 6, 2026, 9:32 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Completion of PMDA consultations is a regulatory milestone that enables submission of a marketing approval application; if approved, CardiAMP would create a new revenue stream in Japan, though timing and approval are uncertain.
AI summary
What happened, with direct paths to the underlying reporting
BioCardia said it completed PMDA consultations on application materials for its CardiAMP cell therapy in Japan and is targeting first patient treatments and commercial revenues in 2028.
BioCardia completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System.
BioCardia is targeting treatment of its first patients in Japan and the realization of commercial revenues in 2028.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
The FDA meeting minutes suggest CardiAMP Heart Failure II trial may support PMA, a potential catalyst for BioCardia's growth. After a year of declines, BCDA shares rallied around…
